The main factors that make congestive heart. Treatment of Heart Failure With Fosinopril
|
|
- Holly Walters
- 5 years ago
- Views:
Transcription
1 AJH 1997;10:236S 241S Treatment of Heart Failure With Fosinopril An Angiotensin Converting Enzyme Inhibitor With a Dual and Compensatory Route of Excretion Giuseppe Mancia, Cristina Giannattasio, and Guido Grassi Congestive heart failure (CHF) is one of the most common and clinically important cardiovascular diseases. This pathologic state is characterized not only by well-defined hemodynamic alterations, but also by complex abnormalities involving the sympathetic nervous system, the renin-angiotensin system, and other hormones involved in cardiovascular homeostasis. In addition, there is an abnormality in the homeostatic cardiovascular control exerted by arterial baroreceptors and the viscoelastic properties of medium-size arteries are altered, causing a reduction in arterial compliance. All of these abnormalities can be favorably affected by angiotensin converting enzyme (ACE) The main factors that make congestive heart failure (CHF) of great clinical importance will be reviewed here. The importance of angiotensin converting enzyme (ACE) inhibitors in the treatment of this condition, and the potential advantages that fosinopril offers, will also be outlined. Although relatively infrequent in young subjects, heart failure becomes progressively more prevalent with age and is one of the most common diseases found in clinical practice in patients 65 years of age. 1 Given the increasing growth of the elderly population, physicians can expect an even greater prevalence of From the Cattedra di Medicina Interna, Ospedale S. Gerardo, Monza, Università di Milano and Centro Fisiologia Clinica e Ipertensione, Ospedale Maggiore IRCCS, Milano, Italy. Address correspondence and reprint requests to Professor Giuseppe Mancia, Cattedra Di Medicina Interna, Ospedale S Gerardo Via Donizett 103, Milano, Italy. inhibitors, which have been shown to improve not only the hemodynamic and neurohumoral profiles of CHF, but also patient survival. CHF is accompanied with a decline or some sort of effect on renal function. An ACE inhibitor with a dual route of excretion, such as fosinopril, may be especially useful in treating patients with CHF. Am J Hypertens 1997;10:236S 241S 1997 American Journal of Hypertension, Ltd. KEY WORDS: Congestive heart failure, sympathetic activity, reflex control of circulation, arterial compliance, angiotensin converting enzyme inhibitors, fosinopril. CHF in the future. In addition, CHF is a very severe disease, with a mortality of approximately 50% at 5 years after diagnosis. 2 The mortality rate depends on the severity of CHF, and in patients with severe CHF (New York Heart Association [NYHA] functional class IV) the mortality rate is as high as 50% 1 year after diagnosis. 3 Finally, CHF has enormous socioeconomic impact because of its high rate of hospitalization. A significant proportion of patients in NYHA class IV will be admitted to the hospital in any year, but hospitalization is also common in less severe cases. Data from the Studies Of Left Ventricular Dysfunction (SOLVD) 4 showed that the yearly hospitalization rate was 61% for patients with NYHA class III CHF and 26% for patients with NYHA class I CHF, ie, the mildest stage. TREATMENT WITH ACE INHIBITORS In recent years, the treatment of CHF has greatly improved. The most important advance has unques by the American Journal of Hypertension, Ltd /97/$17.00 Published by Elsevier Science, Inc. PII S (97)
2 AJH OCTOBER 1997 VOL. 10, NO. 10, PART 2 FOSINOPRIL IN CONGESTIVE HEART FAILURE 237S FIGURE 1. Sensitivity of the baroreceptor heart rate (HR) and muscle sympathetic nerve activity (MSNA) reflex in the three groups of subjects (Control subjects n 17, open histogram; mild CHF n 17, dashed histogram; severe CHF n 19, dark histogram). Baroreflex sensitivity was separately calculated for baroreceptor stimulation (phenylephrine infusion, top) and deactivation (nitroprusside infusion, bottom). MAP, mean arterial pressure. Values are shown as means SEM. (Reproduced from Grassi et al, 9 with permission.) tionably been the introduction of ACE inhibitors. These drugs have allowed many treatment goals to be achieved, for example, reduction in symptoms, increase in exercise tolerance, and improvement in hemodynamic dysfunction. Moreover, ACE inhibitors have increased survival in patients with both severe and mild forms of the disease. 3 5 More recently, the Survival And Ventricular Enlargement (SAVE) and the SOLVD trials have demonstrated the ability of ACE inhibitors to delay the progression of CHF and to reduce overall hospitalization rates. 6,7 A typical feature of more severe CHF is neurohumoral activation of catecholamines, which has been shown to be related to survival. 8 In a study involving three groups of age-matched subjects 9 a control group of healthy subjects, a group with severe CHF, and a group with mild CHF (defined as NYHA class II with a left ventricular ejection fraction of 40%) plasma concentrations of vasopressin, atrial natriuretic peptide, norepinephrine, and renin were all increased in the severe CHF group. Some increases, however, were also seen in the mild CHF group. In particular, sympathetic activity, measured by the microneurographic technique, 10 showed a 40% and 80% increase in mild and severe CHF, respectively, clearly indicating that the increase in plasma norepinephrine was not attributable to a reduction in the clearance rate of the neurotransmitter, 11 but to an increased central sympathetic outflow. The process by which ACE inhibition affects this activation has been addressed in a study in which benazepril was administered for 8 weeks to subjects with mild CHF. In all subjects, sympathetic nerve activity, as measured by microneurography, was reduced by the ACE inhibitor, with an average reduction of approximately 30%. 12,13 The sympathetic nerve traffic reduction was accompanied by the increased ability of arterial baroreceptor stimulation, induced by phenylephrine infusion, to inhibit adrenergic drive. These findings may be important in understanding the pathophysiology of the increase in sympathetic activation characterizing heart failure. One hypothesis is that the sympathetic activation in CHF is attributable to an impairment of the tonic restraint of sympathetic activity by the baroreflex Indeed, compared with control subjects, in patients with severe CHF the ability of baroreceptor stimulation or deactivation to induce reflex bradycardia (sympathetic inhibition) or tachycardia (sympathetic excitation) reflexively is strikingly depressed. A less striking but still clearcut depression, is also apparent in patients with mild CHF (Figure 1). 9 We believe that we have identified at least one mechanism responsible for the baroreflex impairment found in CHF, explaining its reversal by ACE inhibition. Baroreceptors are stretch receptors, responsive to changes in arterial volume and therefore, dependent on arterial distensibility. 14 When arterial distensibility is measured in a radial artery by a technique that allows it to be assessed dynamically, CHF patients show stiffer arteries than control subjects. 17 There is also a clearly inverse relationship between arterial compliance and the baroreflex ability to modulate sympathetic nerve traffic, ie, the lower the compliance, the greater the sympathetic activity (Figure 2). 18 In studies comparing pretreatment responses to isometric stress with fosinopril and isradipine, fosinopril has been shown to preserve the physiologic increase in blood pressure, whereas isradipine failed to do so. With isradipine, blood pressure reached pretreatment stress levels. This augmented pressure increase was associated with an exaggerated stimulation of the sympathetic nervous system during isometric stress that resulted in a marked increase in cardiac output and total peripheral resistance but not heart rate. 19 When an ACE inhibitor is administered to heart
3 238S MANCIA ET AL AJH OCTOBER 1997 VOL. 10, NO. 10, PART 2 failure patients for 8 weeks, arterial compliance markedly increases (Figure 3); this does not occur in normotensive and hypertensive subjects followed over a similar time period. 20 Therefore, it appears that arterial stiffening is, at least in part, responsible for the FIGURE 2. Negative relationship between radial artery compliance, sympathetic nerve traffic (MSNA), bursts per minute [left top] and bursts per 100 heart beats [right top]) and baroreflex sensitivity (bottom) in patients with CHF. Baroreflex sensitivity was measured by averaging the slope of the relationship between 1) the reduction in sympathetic nerve traffic induced by increasing mean arterial pressure through stepwise infusions of phenylephrine (PHE, left bottom) and 2) the increase in sympathetic nerve traffic induced by reducing mean arterial pressure through stepwise infusions of nitroprusside (NTP, right bottom). (Modified from Grassi et al. 18 ) baroreflex failure to modulate adrenergic tone, thus favoring the occurrence of the sympathetic activation characterizing CHF. Reversing this stiffness is one of the mechanisms by which ACE inhibitors exert their beneficial effect. FIGURE 3. Increase in radial arterial compliance after 4 and 8 weeks of daily administration of 10 mg of benazepril in a group of CHF patients (CHF, bottom). Over the same time interval compliance showed no change in a control group of normotensive subjects (C, left top) and a control group of essential hypertensive subjects (H, right top). Data are shown as compliance pressure curves. Results are expressed as means SEM. The increase in the compliance index observed in CHF patients after ACE inhibitor treatment was statistically significant. (Reproduced from Giannattasio et al 20 with permission.)
4 AJH OCTOBER 1997 VOL. 10, NO. 10, PART 2 FOSINOPRIL IN CONGESTIVE HEART FAILURE 239S FIGURE 4. Changes in pulmonary capillary wedge pressure (PCWP), cardiac index (CI), stroke volume index (SVI), mean arterial blood pressure (MABP), heart rate (HR), and mean right atrial pressure (MRAP) after 10 weeks of fosinopril treatment, by daily dosage. (Reproduced from Deedwania, 21 with permission.) FOSINOPRIL AND CHF The ACE inhibitor fosinopril appears particularly promising for the treatment of CHF. Administration of fosinopril, in doses of 1, 20, or 40 mg/day, to subjects with CHF (NYHA 21 class I to class III) was associated with beneficial hemodynamic changes (Figure 4). Fosinopril administration produced a reduction in pulmonary capillary wedge pressure and right atrial pressure, an increase in stroke volume index, and a reduction in heart rate. It is clear from placebo-controlled, randomized, double-blind studies that the clinical manifestations of CHF are also favorably affected by fosinopril. In one study, for example, administration of fosinopril for 6 months caused an increase in exercise duration and a reduction of symptoms significantly greater than that seen in the placebo group. 22 In another study, exercise duration was increased and symptoms reduced when fosinopril was administered for 3 months (Figure 5). 23 Pooling data from the available studies to obtain a larger total number of subjects showed that, in the fosinopril-treated group, the number of cardiovascular events, worsening of CHF and the hospitalization rate were less than that observed in the placebo group. 21 These data suggest that fosinopril produces benefits similar to those previously observed with other ACE inhibitors. Side effects, such as hypotension, acute deterioration in renal function, cough, and angioneurotic edema, have been reported when ACE inhibitors are given to patients with CHF. Although some side effects are not clearly dose related (for example, cough), the dose relationship of side effects such as hypotension and acute deterioration in renal function makes FIGURE 5. Effects of 3 months of fosinopril treatment on clinical symptoms (left) and exercise duration (right) in 308 patients with CHF. Asterisks refer to the level of statistical significance (fosinopril v placebo). (Modified from Erhardt et al. 23 )
5 240S MANCIA ET AL AJH OCTOBER 1997 VOL. 10, NO. 10, PART 2 FIGURE 6. Plot of plasma endothelin (ET) concentrations in two groups of patients before and after 12 weeks of treatment with fosinopril (squares) and placebo (triangles). The 18 patients randomized to fosinopril treatment and the 16 patients randomized to placebo who finished this study have similar baseline plasma ET ( and pg/ml, respectively). Treatment with fosinopril reduced plasma ET to pg/ml (P.005) in contrast to the nonsignificant increase in the group treated with placebo ( pg/ml P NS) (Reproduced from Galatius- Jensen et al 28 with permission.) them progressively more frequent and severe as the plasma concentration of the ACE inhibitor increases. This can create a vicious circle, as renal function in subjects with CHF may already be impaired either because of reduced blood flow or renal disease, thus facilitating accumulation of the ACE inhibitor. In turn, renal function may be further impaired. In this respect, the dual and compensatory route of elimination of fosinopril, excreted through the kidney and through hepatic metabolism, 24,25 may represent an advantage for this ACE inhibitor. Data obtained from a study in which the accumulation of fosinopril was compared to that of enalapril and lisinopril in patients with CHF support this view (Data on file, Bristol Myers-Squibb). The drug accumulation was significantly less for fosinopril than for either enalapril or lisinopril, presumably because the dual and compensatory routes of elimination of fosinopril increase its clearance from the body when renal elimination was impaired. Hypertensive patients with previous ACE inhibitorassociated cough have experienced less frequent cough with fosinopril compared with other ACE inhibitor therapies. 26,27 These studies suggest that the production of coughing may vary among the different ACE inhibitors. Interestingly, recent data have indicated that endothelin may play a role in the progression of CHF, as a significant correlation between plasma endothelin and exercise test duration and composite heart failure score was demonstrated (P.001). 28 Patients with moderately severe CHF (n 34) had significantly (P.0001) elevated endothelin levels compared with a group of controls (n 21); mean levels were 3.5 pg/ml compared with 2.0 pg/ml, respectively. After treatment with fosinopril for 12 weeks, endothelin levels decreased significantly (P.005) to 2.5 pg/ml, compared with a slight increase in the placebo-treated group (Figure 6). This data indicated another possible mechanism for the benefit of ACE inhibitors. Furthermore, available data from placebo-controlled trials in more than 500 patients with CHF, treated for an average of 93 days, not only suggest that worsening of heart failure was much less with fosinopril than with placebo, but also that the two groups had similar rates of side effects. In particular, hypotension, which is a marker of the pharmacologic action of the drug rather than an adverse effect, as well as a marker of the dependence of blood and glomerular filtration pressure on angiotensin II in CHF patients, was relatively infrequent with fosinopril, suggesting good tolerability. 22,23 REFERENCES 1. Ho KKL, Pinsky JL, Kannel WB, et al: The epidemiology of heart failure: the Framingham study. J Am Coll Cardiol 1993;22(suppl A):6A 13A. 2. McKee PA, Castelli WP, McNamara PM, et al: The natural history of congestive heart failure: the Framingham study. N Engl J Med 1971;285: Consensus Trial Study Group: Effects of enalapril in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study. N Engl J Med 1987;316: The SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med 1991;325: The SOLVD Investigators: Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327: Konstam MA, Kronenberg MW, Rousseau MF, et al, for the SOLVD Investigators: effects of the angiotensinconverting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. Circulation 1993;88: Pfeffer MA, Braunwald E, Moyé LA, et al, for the SAVE Investigators: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival And Ven-
6 AJH OCTOBER 1997 VOL. 10, NO. 10, PART 2 FOSINOPRIL IN CONGESTIVE HEART FAILURE 241S tricular Enlargement trial. N Engl J Med 1992;327: Cohn JN, Levine TB, Olivari MT, et al: Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984; 311: Grassi G, Seravalle G, Cattaneo BM, et al: Sympathetic activation and loss of reflex sympathetic control in mild congestive heart failure. Circulation 1995;92: Grassi G, Seravalle G, Calhoun DA, et al: Monitoring of sympathetic activity in man: physiology and pharmacology. Eur Heart J 1992;13(suppl A): Davis D, Baily R, Zelis R: Abnormalities in systemic norepinephrine kinetics in human congestive heart failure. Am J Physiol 1988;254: Grassi G, Lanfranchi A, Seravalle G, et al: Effects of chronic angiotensin-converting enzyme inhibition on sympathetic nerve traffic in congestive heart failure (abst). Eur Heart J 1994;14(suppl): Lanfranchi A, Cattaneo BM, Bolla GB, et al: Effects of angiotensin-converting enzyme inhibition on baroreflex control of circulation in congestive heart failure (abst). Eur Heart J 1995;16(suppl): Mancia G, Mark AL: Arterial baroreflexes in humans, in Shepherd JT, Abboud FM (eds): Handbook of Physiology: The Cardiovascular System, vol. II, part 2. American Physiological Society, Bethesda, MD, 1983, pp Mancia G, Seravalle G, Giannattasio C, et al: Reflex cardiovascular control in congestive heart failure. Am J Cardiol 1992;69:17G 23G. 16. Ferguson DW: Sympathetic mechanisms in heart failure. Pathophysiological and pharmacological implications. Circulation 1993;87(suppl VII): Giannattasio C, Failla M, Stella ML, et al: Alterations of radial artery compliance in patients with congestive heart failure. Am J Cardiol 1995;76: Grassi G, Giannattasio C, Failla M, et al: Sympathetic modulation of radial artery compliance in congestive heart failure. Hypertension 1995;25: Grossman E, Messerli F, Oren S, et al: Disparate cardiovascular response to stress tests during isradipine and fosinopril therapy. Am J Cardiol 1993;72: Giannattasio C, Failla M, Stella ML, et al: Angiotensinconverting enzyme inhibition and radial artery compliance in patients with congestive heart failure. Hypertension 1995;26: Deedwania P: Clinical profile of fosinopril, a novel phosphinic acid ACE-inhibitor for the treatment of heart failure. Heart Failure 1995;11(3): Brown EJ, Chew PH, MacLean A, et al for the Fosinopril Heart Failure Study Group: Effects of fosinopril on exercise tolerance and clinical deterioration in patients with chronic congestive heart failure not taking digitalis. Am J Cardiol 1995;75: Erhardt L, Maclean A, Ilgenfritz J, et al for the Fosinopril Efficacy/Safety Trial (FEST) Study Group: Fosinopril attenuates clinical deterioration and improves exercise tolerance in patients with heart failure. Eur Heart J 1995;16: Duchin KL: Clinical pharmacology of fosinopril. Drug Invest 1991;3(suppl 4): Duchin KL, Kripalani KJ, Marino MR, et al: Review of the pharmacokinetics of fosinopril in special population. Drug Invest 1991;3(suppl 4): David D, Jallad N, Germino FW, et al: A comparison of the cough profile of fosinopril and enalapril in hypertensive patients with a history of ACE inhibitor associated cough. Am J Ther 1995;2: Germino FW, Lastra J, Pool P, et al: Evaluation of the cough profile of fosinopril in hypertensive patients with ACE inhibitor associated cough A pilot study. Curr Ther Res 1993;54: Galatius-Jensen S, Wroblewski H, Emmeluth C, et al: Plasma endothelin in congestive heart failure: effect of the ACE inhibitor, fosinopril. Cardiovasc Res 1996;32:
Calcium antagonists have been regarded as harmful in the
Effects of Amlodipine on Sympathetic Nerve Traffic and Baroreflex Control of Circulation in Heart Failure Guido Grassi, Domenico Spaziani, Gino Seravalle, Giovanni Bertinieri, Raffaella Dell Oro, Cesare
More informationBRIEF COMMUNICATIONS. KEY WORDS: Ambulatory blood pressure monitoring, placebo effect, antihypertensive drug trials.
AJH 1995; 8:311-315 BRIEF COMMUNICATIONS Lack of Placebo Effect on Ambulatory Blood Pressure Giuseppe Mancia, Stefano Omboni, Gianfranco Parati, Antonella Ravogli, Alessandra Villani, and Alberto Zanchetti
More informationData Alert #2... Bi o l o g y Work i n g Gro u p. Subject: HOPE: New validation for the importance of tissue ACE inhibition
Vascular Bi o l o g y Work i n g Gro u p c/o Medical Education Consultants, In c. 25 Sy l van Road South, We s t p o rt, CT 06880 Chairman: Carl J. Pepine, MD Professor and Chief Division of Cardiovascular
More informationSympathetic and reflex abnormalities in heart failure secondary to ischaemic or idiopathic dilated cardiomyopathy
Clinical Science (2001) 101, 141 146 (Printed in Great Britain) 141 Sympathetic and reflex abnormalities in heart failure secondary to ischaemic or idiopathic dilated cardiomyopathy Guido GRASSI*, Gino
More informationVIEWPOINT. Journal of the American College of Cardiology Vol. 37, No. 5, by the American College of Cardiology ISSN /01/$20.
Journal of the American College of Cardiology Vol. 37, No. 5, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00 Published by Elsevier Science Inc. PII S0735-1097(01)01161-5 VIEWPOINT
More informationOptimal blockade of the Renin- Angiotensin-Aldosterone. in chronic heart failure
Optimal blockade of the Renin- Angiotensin-Aldosterone Aldosterone- (RAA)-System in chronic heart failure Jan Östergren Department of Medicine Karolinska University Hospital Stockholm, Sweden Key Issues
More informationHeart Failure. Acute. Plasma [NE] (pg/ml) 24 Hours. Chronic
Heart Failure Heart failure is the inability of the heart to deliver sufficient blood to the tissues to ensure adequate oxygen supply. Clinically it is characterized by signs of volume overload or symptoms
More informationComparison with plasma angiotensin II and endothelin-1
European Heart Journal (1999) 2, 1799 187 Article No. euhj.1999.1746, available online at http://www.idealibrary.com on Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality
More informationAmlodipine plus Lisinopril Tablets AMLOPRES-L
Amlodipine plus Lisinopril Tablets AMLOPRES-L COMPOSITION AMLOPRES-L Each uncoated tablet contains: Amlodipine besylate equivalent to Amlodipine 5 mg and Lisinopril USP equivalent to Lisinopril (anhydrous)
More informationFAILURE IN PATIENTS WITH MYOCARDIAL INFARCTION
Br. J. clin. Pharmac. (1982), 14, 187S-19lS BENEFICIAL EFFECTS OF CAPTOPRIL IN LEFT VENTRICULAR FAILURE IN PATIENTS WITH MYOCARDIAL INFARCTION J.P. BOUNHOURE, J.G. KAYANAKIS, J.M. FAUVEL & J. PUEL Departments
More informationEvidence of Baroreflex Activation Therapy s Mechanism of Action
Evidence of Baroreflex Activation Therapy s Mechanism of Action Edoardo Gronda, MD, FESC Heart Failure Research Center IRCCS MultiMedica Cardiovascular Department Sesto S. Giovanni (Milano) Italy Agenda
More informationHeart Failure (HF) Treatment
Heart Failure (HF) Treatment Heart Failure (HF) Complex, progressive disorder. The heart is unable to pump sufficient blood to meet the needs of the body. Its cardinal symptoms are dyspnea, fatigue, and
More informationThe Treatment Targets in Acute Decompensated Heart Failure
SUCCESS WITH HEART FAILURE The Treatment Targets in Acute Decompensated Heart Failure Gregg C. Fonarow, MD The Ahmanson-UCLA Cardiomyopathy Center, Division of Cardiology, UCLA School of Medicine, Los
More informationORIGINAL INVESTIGATION. Toleration of High Doses of Angiotensin-Converting Enzyme Inhibitors in Patients With Chronic Heart Failure
Toleration of High Doses of Angiotensin-Converting Enzyme Inhibitors in Patients With Chronic Heart Failure Results From the ATLAS Trial ORIGINAL INVESTIGATION Barry M. Massie, MD; Paul W. Armstrong, MD;
More informationMayo Clin Proc, March 2003, Vol 78 Role of ARBs in Treatment of Heart Failure 335 system, tissue-based RAS has long-term effects that can modify cardi
334 Concise Review for Clinicians Therapeutic Role of Angiotensin II Receptor Blockers in the Treatment of Heart Failure Concise Review for Clinicians PRERANA MANOHAR, MD, AND ILEANA L. PIÑA, MD Angiotensin
More informationEntresto Development of sacubitril/valsartan (LCZ696) for the treatment of heart failure with reduced ejection fraction
Cardio-Metabolic Franchise Entresto Development of sacubitril/valsartan (LCZ696) for the treatment of heart failure with reduced ejection fraction Randy L Webb, PhD Rutgers Workshop October 21, 2016 Heart
More informationCatheter Based Denervation for Heart Failure
Catheter Based Denervation for Heart Failure David E. Kandzari, MD, FACC, FSCAI Chief Scientific Officer Director, Interventional Cardiology Piedmont Heart Institute Atlanta, Georgia david.kandzari@piedmont.org
More informationLXIV: DRUGS: 4. RAS BLOCKADE
LXIV: DRUGS: 4. RAS BLOCKADE ACE Inhibitors Components of RAS Actions of Angiotensin i II Indications for ACEIs Contraindications RAS blockade in hypertension RAS blockade in CAD RAS blockade in HF Limitations
More informationDefinition of Congestive Heart Failure
Heart Failure Definition of Congestive Heart Failure A clinical syndrome of signs & symptoms resulting from the heart s inability to supply adequate tissue perfusion. CHF Epidemiology Affects 4.7 million
More informationSYMPATHETIC STRESSORS AND SYMPATHETIC FAILURES
SYMPATHETIC STRESSORS AND SYMPATHETIC FAILURES Any discussion of sympathetic involvement in circulation, and vasodilation, and vasoconstriction requires an understanding that there is no such thing as
More informationCKD Satellite Symposium
CKD Satellite Symposium Recommended Therapy by Heart Failure Stage AHA/ACC Task Force on Practice Guideline 2001 Natural History of Heart Failure Patients surviving % Mechanism of death Sudden death 40%
More informationΔακτυλίτιδα και Ινότροπα Φάρμακα στην Καρδιακή Ανεπάρκεια. Ι.Κανονίδης
Δακτυλίτιδα και Ινότροπα Φάρμακα στην Καρδιακή Ανεπάρκεια Ι.Κανονίδης Cardiac Glycosides Chronic Congestive Heart Failure DIGOXIN Na-K ATPase Na + K + Na-Ca Exchange Na + Ca ++ Ca ++ K + Na + Myofilaments
More information3/10/2009 VESSELS PHYSIOLOGY D.HAMMOUDI.MD. Palpated Pulse. Figure 19.11
VESSELS PHYSIOLOGY D.HAMMOUDI.MD Palpated Pulse Figure 19.11 1 shows the common sites where the pulse is felt. 1. Temporal artery at the temple above and to the outer side of the eye 2. External maxillary
More informationAlthough it is well established that the sympathetic. The Sympathetic Nervous System and Long-Term Blood Pressure Regulation. Thomas E.
AJH 2001; 14:147S 154S The Sympathetic Nervous System and Long-Term Blood Pressure Regulation Thomas E. Lohmeier There is considerable evidence that activation of the sympathetic nervous system plays an
More informationΥπέρταση στις γυναίκες
Υπέρταση στις γυναίκες Ελένη Τριανταφυλλίδη Διευθύντρια ΕΣΥ Καρδιολογίας Υπεύθυνη Αντιυπερτασικού Ιατρείου Β Πανεπιστημιακή Καρδιολογική Κλινική Νοσοκομείο ΑΤΤΙΚΟΝ Cardiovascular disease is the Europe
More informationMEDICINAL PRODUCTS IN THE TREATMENT OF CARDIAC FAILURE
MEDICINAL PRODUCTS IN THE TREATMENT OF CARDIAC FAILURE Guideline Title Medicinal Products in the Treatment of Cardiac Failure Legislative basis Directive 75/318/EEC as amended Date of first adoption November
More informationPaul M McKie, Alessandro Cataliotti, Guido Boerrigter, Horng C Chen, Fernando L Martin, and John C Burnett Jr
Cardiorenal Enhancing and Aldosterone Suppressing Actions of a Novel Designer Natriuretic Peptide in Experimental Hypertension with Ventricular Pressure Overload Paul M McKie, Alessandro Cataliotti, Guido
More information...SELECTED ABSTRACTS...
The following abstracts, from peer-reviewed journals containing literature on vascular compliance and hypertension, were selected for their relevance to this conference and to a managed care perspective.
More informationCopyright 2011, 2007 by Mosby, Inc., an affiliate of Elsevier Inc. Normal Cardiac Anatomy
Mosby,, an affiliate of Elsevier Normal Cardiac Anatomy Impaired cardiac pumping Results in vasoconstriction & fluid retention Characterized by ventricular dysfunction, reduced exercise tolerance, diminished
More informationBaroreflex sensitivity and the blood pressure response to -blockade
Journal of Human Hypertension (1999) 13, 185 190 1999 Stockton Press. All rights reserved 0950-9240/99 $12.00 http://www.stockton-press.co.uk/jhh ORIGINAL ARTICLE Baroreflex sensitivity and the blood pressure
More informationThe right heart: the Cinderella of heart failure
The right heart: the Cinderella of heart failure Piotr Ponikowski, MD, PhD, FESC Medical University, Centre for Heart Disease Clinical Military Hospital Wroclaw, Poland none Disclosure Look into the Heart
More informationHeart Failure. Cardiac Anatomy. Functions of the Heart. Cardiac Cycle/Hemodynamics. Determinants of Cardiac Output. Cardiac Output
Cardiac Anatomy Heart Failure Professor Qing ZHANG Department of Cardiology, West China Hospital www.blaufuss.org Cardiac Cycle/Hemodynamics Functions of the Heart Essential functions of the heart to cover
More informationEffects of Cilostazol in Patients With Bradycardiac Atrial Fibrillation
J Cardiol 2001 ; 37: 27 33 Effects of Cilostazol in Patients With Bradycardiac Atrial Fibrillation 1 2 1 Masato Kouki KISHIDA, MD WATANABE, MD Abstract Objectives. Cilostazol, an antithrombotic agent,
More information(D) (E) (F) 6. The extrasystolic beat would produce (A) increased pulse pressure because contractility. is increased. increased
Review Test 1. A 53-year-old woman is found, by arteriography, to have 5% narrowing of her left renal artery. What is the expected change in blood flow through the stenotic artery? Decrease to 1 2 Decrease
More informationCardiac Output MCQ. Professor of Cardiovascular Physiology. Cairo University 2007
Cardiac Output MCQ Abdel Moniem Ibrahim Ahmed, MD Professor of Cardiovascular Physiology Cairo University 2007 90- Guided by Ohm's law when : a- Cardiac output = 5.6 L/min. b- Systolic and diastolic BP
More informationHeart failure (HF) is the only cardiovascular. The Progression From Hypertension to Heart Failure Prakash C. Deedwania
AJH 1997;10:280S 288S The Progression From Hypertension to Heart Failure Prakash C. Deedwania Heart failure (HF) still presents a major health problem despite significant understanding of its underlying
More informationLab Period: Name: Physiology Chapter 14 Blood Flow and Blood Pressure, Plus Fun Review Study Guide
Lab Period: Name: Physiology Chapter 14 Blood Flow and Blood Pressure, Plus Fun Review Study Guide Main Idea: The function of the circulatory system is to maintain adequate blood flow to all tissues. Clinical
More informationANGIOTENSIN II RECEPTOR BLOCKERS: MORE THAN THE ALTERNATIVE PRESENTATION BY: PATRICK HO, USC PHARM D. CANDIDATE OF 2017 MENTOR: DR.
ANGIOTENSIN II RECEPTOR BLOCKERS: MORE THAN THE ALTERNATIVE PRESENTATION BY: PATRICK HO, USC PHARM D. CANDIDATE OF 2017 MENTOR: DR. CRAIG STERN, PHARMD, MBA, RPH, FASCP, FASHP, FICA, FLMI, FAMCP RENIN-ANGIOTENSIN
More informationβ adrenergic blockade, a renal perspective Prof S O McLigeyo
β adrenergic blockade, a renal perspective Prof S O McLigeyo Carvedilol Third generation β blocker (both β 1 and β 2 ) Possesses α 1 adrenergic blocking properties. β: α blocking ratio 7:1 to 3:1 Antioxidant
More informationProceeding of the LAVC Latin American Veterinary Conference Oct , 2009 Lima, Peru
Close this window to return to IVIS www.ivis.org Proceeding of the LAVC Latin American Veterinary Conference Oct. 16-19, 2009 Lima, Peru Reprinted in the IVIS website with the permission of the LAVC http://www.ivis.org/
More informationAntihypertensive Agents Part-2. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Antihypertensive Agents Part-2 Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Agents that block production or action of angiotensin Angiotensin-converting
More informationDuring exercise the heart rate is 190 bpm and the stroke volume is 115 ml/beat. What is the cardiac output?
The Cardiovascular System Part III: Heart Outline of class lecture After studying part I of this chapter you should be able to: 1. Be able to calculate cardiac output (CO) be able to define heart rate
More informationTopic Page: congestive heart failure
Topic Page: congestive heart failure Definition: congestive heart f ailure from Merriam-Webster's Collegiate(R) Dictionary (1930) : heart failure in which the heart is unable to maintain an adequate circulation
More informationAge-related changes in cardiovascular system. Dr. Rehab Gwada
Age-related changes in cardiovascular system Dr. Rehab Gwada Objectives explain the main structural and functional changes in cardiovascular system associated with normal aging Introduction aging results
More informationHeart Failure. Subjective SOB (shortness of breath) Peripheral edema. Orthopnea (2-3 pillows) PND (paroxysmal nocturnal dyspnea)
Pharmacology I. Definitions A. Heart Failure (HF) Heart Failure Ezra Levy, Pharm.D. HF Results when one or both ventricles are unable to pump sufficient blood to meet the body s needs There are 2 types
More informationCardiovascular System B L O O D V E S S E L S 2
Cardiovascular System B L O O D V E S S E L S 2 Blood Pressure Main factors influencing blood pressure: Cardiac output (CO) Peripheral resistance (PR) Blood volume Peripheral resistance is a major factor
More informationRegulation of Arterial Blood Pressure 2 George D. Ford, Ph.D.
Regulation of Arterial Blood Pressure 2 George D. Ford, Ph.D. OBJECTIVES: 1. Describe the Central Nervous System Ischemic Response. 2. Describe chemical sensitivities of arterial and cardiopulmonary chemoreceptors,
More informationManaging Hypertension in the Perioperative Arena
Managing Hypertension in the Perioperative Arena Optimizing Perioperative Management Strategies for Hypertension in the Cardiac Surgical Patient Objectives: Treatment of hypertensive emergencies. ALBERT
More informationPost Hoc Analysis of the PARADIGM Heart Failure Trial:
Post Hoc Analysis of the PARADIGM Heart Failure Trial: Pulse Pressure and Outcomes in Heart Failure with Reduced Ejection Fraction Chen-Huan Chen, M.D. Professor, Department of Medicine, National Yang-Ming
More informationPreventing the cardiovascular complications of hypertension
European Heart Journal Supplements (2004) 6 (Supplement H), H37 H42 Preventing the cardiovascular complications of hypertension Peter Trenkwalder* Department of Internal Medicine, Starnberg Hospital, Ludwig
More information20 ng/ml 200 ng/ml 1000 ng/ml chronic kidney disease CKD Brugada 5 Brugada Brugada 1
Symposium 39 45 1 1 2005 2008 108000 59000 55 1 3 0.045 1 1 90 95 5 10 60 30 Brugada 5 Brugada 80 15 Brugada 1 80 20 2 12 X 2 1 1 brain natriuretic peptide BNP 20 ng/ml 200 ng/ml 1000 ng/ml chronic kidney
More informationIntroduction. Invasive Hemodynamic Monitoring. Determinants of Cardiovascular Function. Cardiovascular System. Hemodynamic Monitoring
Introduction Invasive Hemodynamic Monitoring Audis Bethea, Pharm.D. Assistant Professor Therapeutics IV January 21, 2004 Hemodynamic monitoring is necessary to assess and manage shock Information obtained
More informationJournal of the American College of Cardiology Vol. 35, No. 3, by the American College of Cardiology ISSN /00/$20.
Journal of the American College of Cardiology Vol. 35, No. 3, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(99)00608-7 The Prognostic
More informationManagement of Stage B Heart Failure
KSC 2017 Management of Stage B Heart Failure Byung Su Yoo, MD., PhD. Division of Cardiology, Wonju College of Medicine, Yonsei University, South Korea Focused on Symptom ASLVSD, ASLVDD LVH HF progression
More informationInnovation therapy in Heart Failure
Innovation therapy in Heart Failure P. Laothavorn September 2015 Topics of discussion Basic Knowledge about heart failure Standard therapy New emerging therapy References: standard Therapy in Heart Failure
More informationDrugs acting on the reninangiotensin-aldosterone
Drugs acting on the reninangiotensin-aldosterone system John McMurray Eugene Braunwald Scholar in Cardiovascular Diseases, Brigham and Women s Hospital, Boston & Visiting Professor, Harvard Medical School
More informationImages have been removed from the PowerPoint slides in this handout due to copyright restrictions.
Heart Failure Heart Failure Introduction and History AHA 2015 Statistics About 6 million Americans 870,000 new cases each year 1 in 9 deaths related to HF Almost 1 million hospitalizations each year (cost
More informationDiagnosis is it really Heart Failure?
ESC Congress Munich - 25-29 August 2012 Heart Failure with Preserved Ejection Fraction From Bench to Bedside Diagnosis is it really Heart Failure? Prof. Burkert Pieske Department of Cardiology Med.University
More informationCombination therapy Giuseppe M.C. Rosano, MD, PhD, MSc, FESC, FHFA St George s Hospitals NHS Trust University of London
Combination therapy Giuseppe M.C. Rosano, MD, PhD, MSc, FESC, FHFA St George s Hospitals NHS Trust University of London KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email:
More information- Dr Alia Shatnawi. 1 P a g e
- 1 مها أبو عجمية - - - Dr Alia Shatnawi 1 P a g e A Skippable Intr0 Blood pressure normally decreases during the night. Absence of this phenomenon is called (nondipping) Wikipedia: Circadian rhythm....
More informationACE inhibitors: still the gold standard?
ACE inhibitors: still the gold standard? Session: Twenty-five years after CONSENSUS What have we learnt about the RAAS in heart failure? Lars Køber, MD, D.Sci Department of Cardiology Rigshospitalet University
More informationAntihypertensive drugs SUMMARY Made by: Lama Shatat
Antihypertensive drugs SUMMARY Made by: Lama Shatat Diuretic Thiazide diuretics The loop diuretics Potassium-sparing Diuretics *Hydrochlorothiazide *Chlorthalidone *Furosemide *Torsemide *Bumetanide Aldosterone
More informationTherapeutic Targets and Interventions
Therapeutic Targets and Interventions Ali Valika, MD, FACC Advanced Heart Failure and Pulmonary Hypertension Advocate Medical Group Midwest Heart Foundation Disclosures: 1. Novartis: Speaker Honorarium
More informationScientific conclusions and detailed explanation of the scientific grounds for the differences from the PRAC recommendation
Annex I Scientific conclusions, grounds for variation to the terms of the marketing authorisations and detailed explanation of the scientific grounds for the differences from the PRAC recommendation 1
More informationDOWNLOAD PDF ABC OF HEART FAILURE
Chapter 1 : The ABCs of managing systolic heart failure: Past, present, and future Heart failure is a multisystem disorder which is characterised by abnormalities of cardiac, skeletal muscle, and renal
More informationBlood Pressure Regulation 2. Faisal I. Mohammed, MD,PhD
Blood Pressure Regulation 2 Faisal I. Mohammed, MD,PhD 1 Objectives Outline the intermediate term and long term regulators of ABP. Describe the role of Epinephrine, Antidiuretic hormone (ADH), Renin-Angiotensin-Aldosterone
More informationBlood Pressure Regulation 2. Faisal I. Mohammed, MD,PhD
Blood Pressure Regulation 2 Faisal I. Mohammed, MD,PhD 1 Objectives Outline the intermediate term and long term regulators of ABP. Describe the role of Epinephrine, Antidiuretic hormone (ADH), Renin-Angiotensin-Aldosterone
More informationBeta 1 Beta blockers A - Propranolol,
Pharma Lecture 3 Beta blockers that we are most interested in are the ones that target Beta 1 receptors. Beta blockers A - Propranolol, it s a non-selective competitive antagonist of beta 1 and beta 2
More informationBaroreflex Activation Therapy: Integrated Autonomic Neuromodulation for Heart Failure and Hypertension
Baroreflex Activation Therapy: Integrated Autonomic Neuromodulation for Heart Failure and Hypertension Robert S. Kieval, VMD, PhD Founder & Chief Technology Officer, CVRx, Inc. Financial Disclosure I,
More informationChanges in Blood Pressure and Vascular Physiology: Markers for Cardiovascular Disease
...SYMPOSIUM PROCEEDINGS... Changes in Blood Pressure and Vascular Physiology: Markers for Cardiovascular Disease Based on a presentation by Joseph L. Izzo, Jr., MD Presentation Summary Changes in systolic
More informationARxCH. Annual Review of Changes in Healthcare. Entresto: An Overview for Pharmacists
Entresto: An Overview for Pharmacists David Comshaw, PharmD Candidate 2019 1 Gyen Musgrave, PharmD Candidate 2019 1 Suzanne Surowiec, PharmD, BCACP 1 Jason Guy, PharmD 1 1 University of Findlay College
More informationSince the initial description of angiotensin II mediated
CLINICAL CARDIOLOGY: PHYSICIAN UPDATE Manipulation of the Renin-Angiotensin System Michael M. Givertz, MD Since the initial description of angiotensin II mediated hypertension 40 years ago, basic and clinical
More informationProperties of Pressure
OBJECTIVES Overview Relationship between pressure and flow Understand the differences between series and parallel circuits Cardiac output and its distribution Cardiac function Control of blood pressure
More informationHuman muscle sympathetic nerve activity (MSNA) arises
Sympathetic Neural Burst Amplitude Distribution A More Specific Indicator of Sympathoexcitation in Human Heart Failure Yrsa Bergmann Sverrisdóttir, PhD; Bengt Rundqvist, MD, PhD; Gudmundur Johannsson,
More informationDisclosure of Relationships
Disclosure of Relationships Over the past 12 months Dr Ruilope has served as Consultant and Speakers Bureau member of Astra-Zeneca, Bayer, Daiichi-Sankyo, Menarini, Novartis, Otsuka, Pfizer, Relypsa, Servier
More informationBlood Pressure Regulation. Faisal I. Mohammed, MD,PhD
Blood Pressure Regulation Faisal I. Mohammed, MD,PhD 1 Objectives Outline the short term and long term regulators of BP Know how baroreceptors and chemoreceptors work Know function of the atrial reflex.
More informationSymBioSys Exercise 2 Cardiac Function Revised and reformatted by C. S. Tritt, Ph.D. Last updated March 20, 2006
SymBioSys Exercise 2 Cardiac Function Revised and reformatted by C. S. Tritt, Ph.D. Last updated March 20, 2006 The goal of this exercise to explore the behavior of the heart as a mechanical pump. For
More informationPOSITION STATEMENT ON ACE-INHIBITORS (Updated December 2002)
POSITION STATEMENT ON ACE-INHIBITORS (Updated December 2002) Well designed, large scale, randomized double-blind, placebo-controlled trials have validated the efficacy of the ACE-inhibitor enalapril in
More informationVeins. VENOUS RETURN = PRELOAD = End Diastolic Volume= Blood returning to heart per cardiac cycle (EDV) or per minute (Venous Return)
Veins Venous system transports blood back to heart (VENOUS RETURN) Capillaries drain into venules Venules converge to form small veins that exit organs Smaller veins merge to form larger vessels Veins
More informationSection 3, Lecture 2
59-291 Section 3, Lecture 2 Diuretics: -increase in Na + excretion (naturesis) Thiazide and Related diuretics -decreased PVR due to decreases muscle contraction -an economical and effective treatment -protect
More informationESC Guidelines for the Diagnosis and Treatment of Chronic Heart Failure
ESC Guidelines for the Diagnosis and Treatment of Chronic Heart Failure - 2005 Karl Swedberg Professor of Medicine Department of Medicine Sahlgrenska University Hospital/Östra Göteborg University Göteborg
More informationThe Who, How and When of Advanced Heart Failure Therapies. Disclosures. What is Advanced Heart Failure?
The Who, How and When of Advanced Heart Failure Therapies 9 th Annual Dartmouth Conference on Advances in Heart Failure Therapies Dartmouth-Hitchcock Medical Center Lebanon, NH May 20, 2013 Joseph G. Rogers,
More informationPre-discussion questions
Amanda Bartlett, PA-C Dustin Bartlett, PA-C Andrea Applegate, PA-C Leslie Yearta Brown, NP CHF Round Table Discussion Objectives ANDREA- Discuss the definition and different categories of CHF DUSTIN- Define
More informationFrom PARADIGM-HF to Clinical Practice. Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group
From PARADIGM-HF to Clinical Practice Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group PARADIGM-HF: Inclusion Criteria Chronic HF NYHA FC II IV with LVEF
More informationBlood Pressure Fox Chapter 14 part 2
Vert Phys PCB3743 Blood Pressure Fox Chapter 14 part 2 T. Houpt, Ph.D. 1 Cardiac Output and Blood Pressure How to Measure Blood Pressure Contribution of vascular resistance to blood pressure Cardiovascular
More informationTreating HF Patients with ARNI s Why, When and How?
Treating HF Patients with ARNI s Why, When and How? 19 th Annual San Diego Heart Failure Symposium for Primary Care Physicians January 11-12, 2019 La Jolla, CA Barry Greenberg M.D. Distinguished Professor
More informationHyponatremia as a Cardiovascular Biomarker
Hyponatremia as a Cardiovascular Biomarker Uri Elkayam, MD Professor of Medicine University of Southern California Keck School of Medicine elkayam@usc.edu Disclosure Research grant from Otsuka for the
More informationHypertension: What s new since JNC 7. Harold M. Szerlip, MD, FACP, FCCP, FASN, FNKF
Hypertension: What s new since JNC 7 Harold M. Szerlip, MD, FACP, FCCP, FASN, FNKF Disclosures Spectral Diagnostics Site investigator Eli Lilly Site investigator ACP IM ITE writing committee NBME Step
More informationThe incidence of transient myocardial ischemia,
AJH 1999;12:50S 55S Heart Rate and the Rate-Pressure Product as Determinants of Cardiovascular Risk in Patients With Hypertension William B. White Inability to supply oxygen to the myocardium when demand
More information1. Antihypertensive agents 2. Vasodilators & treatment of angina 3. Drugs used in heart failure 4. Drugs used in arrhythmias
1. Antihypertensive agents 2. Vasodilators & treatment of angina 3. Drugs used in heart failure 4. Drugs used in arrhythmias Only need to know drugs discussed in class At the end of this section you should
More informationSalt Sensitivity: Mechanisms, Diagnosis, and Clinical Relevance
Salt Sensitivity: Mechanisms, Diagnosis, and Clinical Relevance Matthew R. Weir, MD Professor and Director Division of Nephrology University of Maryland School of Medicine Overview Introduction Mechanisms
More informationHYPERTENSION: Sustained elevation of arterial blood pressure above normal o Systolic 140 mm Hg and/or o Diastolic 90 mm Hg
Lecture 39 Anti-Hypertensives B-Rod BLOOD PRESSURE: Systolic / Diastolic NORMAL: 120/80 Systolic = measure of pressure as heart is beating Diastolic = measure of pressure while heart is at rest between
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Blood Pressure Control role of specific antihypertensives
Blood Pressure Control role of specific antihypertensives Date written: May 2005 Final submission: October 2005 Author: Adrian Gillian GUIDELINES a. Regimens that include angiotensin-converting enzyme
More informationCombination of renin-angiotensinaldosterone. how to choose?
Combination of renin-angiotensinaldosterone system inhibitors how to choose? Karl Swedberg Professor of Medicine Sahlgrenska Academy University of Gothenburg karl.swedberg@gu.se Disclosures Research grants
More informationEjection Fraction in Patients With Chronic Heart Failure. Diastolic Heart Failure or Heart Failure with Preserved Ejection Fraction
Diastolic Heart Failure or Heart Failure with Preserved Ejection Fraction Keith Miller MD Diastolic Heart Failure Risk Factors Common Risk Factors Aging Female gender Obesity Hypertension Diabetes mellitus
More informationMedical Management of Acute Heart Failure
Critical Care Medicine and Trauma Medical Management of Acute Heart Failure Mary O. Gray, MD, FAHA Associate Professor of Medicine University of California, San Francisco Staff Cardiologist and Training
More informationBlood Pressure Regulation. Slides 9-12 Mean Arterial Pressure (MAP) = 1/3 systolic pressure + 2/3 diastolic pressure
Sheet physiology(18) Sunday 24-November Blood Pressure Regulation Slides 9-12 Mean Arterial Pressure (MAP) = 1/3 systolic pressure + 2/3 diastolic pressure MAP= Diastolic Pressure+1/3 Pulse Pressure CO=MAP/TPR
More informationSatish K Surabhi, MD.FACC,FSCAI,RPVI Medical Director, Cardiac Cath Labs AnMed Health Heart & Vascular Care
Satish K Surabhi, MD.FACC,FSCAI,RPVI Medical Director, Cardiac Cath Labs AnMed Health Heart & Vascular Care None Fig. 1. Progression of Heart Failure.With each hospitalization for acute heart failure,
More informationThe Exercise Pressor Reflex
The Exercise Pressor Reflex Dr. James P. Fisher School of Sport, Exercise & Rehabilitation Sciences College of Life & Environmental Sciences University of Birmingham, UK Copenhagen, 2018 Based on work
More informationCARDIOVASCULAR SYSTEM
CARDIOVASCULAR SYSTEM 1. Resting membrane potential of the ventricular myocardium is: A. -55 to-65mv B. --65 to-75mv C. -75 to-85mv D. -85 to-95 mv E. -95 to-105mv 2. Regarding myocardial contraction:
More information